Abstract: The invention provides methods for using virus-like particle (VLP) vaccines containing a stabilized pre-fusion respiratory syncytial virus (RSV) F protein to stimulate RSV neutralizing antibodies in pre-immune subjects.

Abstract: The present invention relates i. a. to an immunogenic composition comprising: a) one or more antigens of avibacterium paragallinarum and one or more antigens of avian encephalomyelitis virus and one or more antigens of fowl pox virus; and b) a pharmaceutically acceptable carrier. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by avibacterium paragallinarum, avian encephalomyelitis virus and fowl pox virus in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.

Abstract: Embodiments of the disclosure relate to the domain of virology of Paramyxoviruses. The disclosure concerns a method for producing self-assembling paramyxoviral particles and a method for identifying a compound able to inhibit the replication or the transcription of a Paramyxovirus. The disclosure also pertains to the nucleocapsid-like particles obtainable by the method of the invention and their use for biotechnological and pharmaceutical applications.

Abstract: The present invention provides compositions and methods for using prophylactic and/or therapeutic vaccines to immunize subjects, and offspring of immunized female subjects, against respiratory syncytial virus (RSV). The invention also provides compositions and methods for producing increased yields of recombinant virus-like particles (VLPs).

Abstract: The present invention relates to prophylactic and/or therapeutic vaccines that contain Newcastle disease Virus (NDV) virus-like particles (VLPs) comprising one or more Epstein-Barr Virus (EBV) antigens. In one embodiment, the invention provides a recombinant virus-like particle (VLP) comprising, in operable combination, a) Newcastle disease virus (NDV) matrix (M) protein, and b) one or more Epstein-Barr Virus (BBV) antigens. The invention's prophylactic and/or therapeutic vaccines are useful for preventing and/or treating infection with EBV and/or disease associated Epstein-Barr Virus, such as cancer.

Abstract: A method, apparatus and system for delivery of live or attenuated viral and bacterial vaccines to fowl are described.

Abstract: The invention provides methods for using virus-like particle (VLP) vaccines containing a stabilized pre-fusion respiratory syncytial virus (RSV) F protein to stimulate RSV neutralizing antibodies in pre-immune subjects.

Abstract: The present invention encompasses NDV vaccines. The vaccine may be a subunit vaccine based on HN of NDV. The NDV HN may be expressed in plants or algae including microalgae. The invention also encompasses recombinant vectors encoding and expressing NDV antigens, epitopes or immunogens which can be used to protect animals against NDV. It encompasses also a vaccination regime compatible with the DIVA strategy, including a prime-boost scheme using viral vector or inactivated vaccines and subunit vaccines.

Abstract: The present inaveation relates to prophylactic and/or therapeutic vaccines thatpoatairj Newcastle disease Virus (NDV) virus-like particles (VLPs) comprising one or more Epstein-Barr Virus (EBV) antigens, in one embodiment, the invention provides a recombinant virus-like particle (V'UP) comprising, i is operable combination, a) Newcastle disease virus? iNDVj matrix (M) protein, and b) one or more Epstein-Barr Virus (BBV) antigens. The im'eniion's prophylactic and/or therapeutic vacclrses are useful for preventing asc/or treatmg, infection with EBY aixi/or disease associated Epstein-Barr Virus, such as cancer.

Abstract: This invention relates to novel unique strains avian reoviridae that were isolated from severe cases of Runting Stunting Syndrome. The present invention also relates to the isolation and uses of novel unique avian reoviridae, diagnostic assays using nucleotide or amino acid specific components of such viruses, such as the sequence encoding Sigma C capsid protein and to vaccines that protect birds from diseases caused by such viruses.

Abstract: A method for preparing a vaccine composition to be implemented in a locally administered treatment for avian viral disease, includes at least the step of: a) extemporaneously mixing a vaccine, including at least one live virus selected from a virus belonging to one or more strains of the avian disease, with an adjuvant diluent (DA), characterized in that the adjuvant diluent is a continuous aqueous phase oil-in-water emulsion or oil-in-water microemulsion.

Abstract: A vaccine composition for birds comprising as an active ingredient a structure containing O-antigen derived from Gram-negative bacteria, provided that said structure does not contain a whole cell, and a process for preparing the same are provided. By using a structure containing O-antigen (e.g. lipopolysaccharide) derived from Gram-negative bacteria as an active ingredient in accordance with the present invention, alleviation of inoculation reaction and reduction in an amount of injection are attained as compared to the conventional whole-cells vaccine to thereby allow for the increase in the number of other antigens to be mixed therewith.

Abstract: The present invention encompasses recombinant Newcastle Disease Virus-Herpesvirus vaccines or compositions. The invention encompasses recombinant NDV vectors encoding and expressing herpesvirus pathogen, antigens, proteins, epitopes or immunogens. Such vaccines or compositions can be used to protect animals against disease.

Abstract: The present invention relates to methods and compositions for use in inducing tumor-specific antibody mediated complement-dependent cytotoxic response in an animal having a tumor comprising administering to said animal a composition comprising a replication competent oncolytic virus wherein administration of the composition induces in the animal production of antibodies that mediate a CDC response specific to said tumor.

Abstract: The present invention is directed to a composition, kit and method for delivering a soft flowable gel to a flock of poultry in barns, but can also be used in hatcheries or free range farms, for treating poultry with a therapeutic agent. The soft flowable gel comprises water, a gelling agent, a therapeutic agent and between about 0.05% and 0.15% xanthan gum.

Abstract: The present invention encompasses engineered Newcastle Disease Virus (NDV) vaccines or compositions. The vaccine or composition may be a recombinant vaccine. The invention also encompasses recombinant vectors encoding and expressing avian pathogen antigens, more specifically avian influenza proteins, epitopes or immunogens. Such vaccines or compositions can be used to protect animals, in particular avian, against disease.

Abstract: The present invention relates to immunostimulatory oligodeoxynucleotides, vectors and vaccines comprising such oligodeoxynucleotides, to their use as a medicament, to their use in preventing or combating infectious disease, to methods for the detection of such oligodeoxynucleotides and to cells to be used in these method.

Abstract: The present invention relates to immunostimulatory oligodeoxynucleotides, vectors and vaccines comprising such oligodeoxynucleotides, to their use as a medicament, to their use in preventing or combating infectious disease, to methods for the detection of such oligodeoxynucleotides and to cells to be used in these methods.

Abstract: A live or inactivated recombinant vaccine is described, comprising a viral vector and a pharmaceutically acceptable vehicle, adjuvant and/or excipient, wherein the viral vector is capable of generating a cell immune response due to an increased alpha and/or gamma interferon production, and is capable of a quick replication, and it has inserted a nucleotide sequence of the ORF 5 and ORF 6 from PRSS.

Abstract: The present invention relates to immunostimulatory oligodeoxynucleotides, vectors and vaccines comprising such oligodeoxynucleotides, to their use as a medicament, to their use in preventing or combating infectious disease and to methods for the detection of such oligodeoxynucleotides.

Abstract: A vaccination method is provided. The method comprises administering to a mammal a histone deacytelase inhibitor in conjunction with a vaccine that expresses an antigen to which the mammal has a pre-existing immunity.

Abstract: The present invention pertains to an emulsion comprising an aqueous phase and an oily phase, the aqueous phase containing a non-live medicinal substance, wherein the aqueous phase comprises at least 30% w/w sugar. The invention also pertains to a method to shield a medicinal substance present in an aqueous phase emulsified with an oily phase, from interaction with the oily phase, and to a vaccine comprising as an antigen a killed micro-organism or a subunit of a micro-organism, the antigen being present in an aqueous phase that is dispersed in an oily phase, wherein the aqueous phase comprises at least 30% w/w sugar.

Abstract: Disclosed are compositions, vectors, kits, and methods for inducing an immune response against avian infectious bronchitis virus (IBV). In particular, the compositions, vectors, kits, and methods may be utilized to immunize poultry against disease associated with IBV infection or to protect poultry from IBV infection altogether.

Abstract: The disclosure relates to a composition added to animal feed used in combination with a vaccine to enhance the effectiveness of the vaccine. Amongst other effects, the composition raises the titer of antibodies to the vaccine.

Abstract: The present invention relates to a new Newcastle disease viruses of any genotype and novel fragments of the Newcastle disease virus genome encoding for the F and HN proteins constructed by reverse genetics and recombination, highly antigenic, for preparing vaccines for the prevention of the Newcastle disease by reducing viral shedding or for using as vectors with other viruses, lyophilized or in oil emulsion. Likewise, it can be used as vector in combination with other pathogenic agents.

Abstract: The invention provides RSV fusion (F) protein ectodomain polypeptide sequences and nucleotide sequences encoding them, as well as cells containing the invention's polypeptide and nucleotide sequences. The invention further provides VLPs that contain the invention's polypeptides, and methods for using the VLPs for protein expression and vaccine formulation. Also provided are methods for distinguishing between subjects immunized with the invention's compositions and subjects infected with RSV.

Abstract: The present invention relates to the generation of replication-competent viruses having therapeutic utility. The replication-competent viruses of the invention can express proteins useful in the treatment of disease.

Abstract: A method for preparing a vaccine composition to be implemented in a locally administered treatment for avian viral disease, includes at least the step of: a) extemporaneously mixing a vaccine, including at least one live virus selected from a virus belonging to one or more strains of the avian disease, with an adjuvant diluent (DA), characterized in that the adjuvant diluent is a continuous aqueous phase oil-in-water emulsion or oil-in-water microemulsion.

Abstract: The present invention relates to pharmaceutical compositions comprising an immunizing amount of inactivated Newcastle disease and an adjuvant for use in the protection of poultry against Newcastle disease, to the use of an immunogenic amount of an inactivated Newcastle disease virus and an adjuvant for the manufacture of a booster vaccine for the vaccination of a chicken or turkey, and to a kit-of-parts comprises a container comprising an inactivated Newcastle disease virus and an adjuvant for a priming vaccination of a chicken or turkey and a container comprising an inactivated Newcastle disease virus and an adjuvant for a boosting vaccination of a chicken or turkey.

Abstract: The present invention is directed to a composition, kit and method for delivering a soft flowable gel to a flock of poultry in barns, but can also be used in hatcheries or free range farms, for treating poultry with a therapeutic agent. The soft flowable gel comprises water, a gelling agent, a therapeutic agent and between about 0.05% and 0.15% xanthan gum.

Abstract: The present invention relates to a recombinant vector for transcription of the Newcastle disease virus (NDV) genome, a strain of attenuated recombinant NDV with a surface antigen of pathogenic NDV prepared by the vector, a method of preparing a recombinant NDV having low pathogenicity and high protectivity efficiency against Newcastle disease (ND) using the vector, and a vaccine against ND containing the recombinant NDV.

Abstract: The present invention relates to an antibody fusion protein which specifically recognizes the VA, HN or F surface antigen of the New Castle Disease Virus (NDV), a surface molecule of a tumor-unspecific T cell or a surface molecule of a dendritic cell and an immunocytokine. Also encompassed by the present invention are polynucleotides encoding the aforementioned antibody fusion protein as well as tumor-unspecific key cells or dendritic cells bound by the antibody fusion protein. Moreover, the present invention relates to a method of treating a tumor in a subject comprising administering to the said subject the antibody fusion protein, the tumor-unspecific T cell, the dendritic cell or the polynucleotide of the invention. Preferably, the said tumor is a solid tumor.

Abstract: The present invention relates to a method of immune activation which is effective for eliciting a non-antigen-specific immune response in a member of the avian species. The method is particularly effective for protecting a member of the avian species from infectious disease and treating animals inflicted with infectious disease.

Abstract: We disclose synthetic peptide fragments comprising amino acid sequences of specific antigen sites of pathogenic Newcastle disease virus in birds, and more particularly synthetic peptide fragments that comprise polybasic amino acid sequences at the cleavage site of the F protein of pathogenic Newcastle disease virus and that induce humoral immune responses in hosts while reacting only with antibodies to pathogenic Newcastle disease virus and are useful to differentiate infected individuals from vaccinated individuals.

Abstract: The present invention relates generally to the fields of immunology and vaccine technology. More specifically, the invention relates to mucosal administration via aerosol spray to avians of immunogenic and vaccine compositions, including those comprising recombinant human adenovirus vectors for delivery of genes encoding avian immunogens or antigens, such as genes encoding avian influenza virus. The invention also provides methods and apparatus for use in such administration.

Abstract: The present invention relates to an epitope of HN protein in Newcastle disease virus which can be recognized by an avian immune system and an antibody against the epitope, a method for detecting a Newcastle disease virus by using the antibody, and an antigenic variant of Newcastle disease virus carrying changes in the epitope. The epitope of HN protein and the antigenic variant of Newcastle disease virus can be used for developing efficient vaccines, and further, in diagnosing the Newcastle disease virus rapidly and exactly.

Abstract: The invention relates to vaccine compositions comprising chitosan and a vaccine which are administered to avian species via the ocular route, and methods or programs of vaccination including use of chitosan in order to increase or enhance cell-mediated immunity in avian species and persistence of the vaccine avian tissues.

Abstract: The present invention encompasses NDV vaccines. The vaccine may be a subunit vaccine based on HN of NDV. The NDV HN may be expressed in plants or algae including microalgae. The invention also encompasses recombinant vectors encoding and expressing NDV antigens, epitopes or immunogens which can be used to protect animals against NDV. It encompasses also a vaccination regime compatible with the DIVA strategy, including a prime-boost scheme using viral vector or inactivated vaccines and subunit vaccines.

Abstract: This invention provides a dry powder composition for poultry vaccination via inhalation comprising an effective amount of a poultry vaccine agent, and a supporting amount of carriers for said poultry vaccine agent, said carriers comprising a combination of a reducing or non-reducing sugar and a biocompatible polymer, said dry powder composition being in the form of particles having an average particle size from 2 to 30 ?m and a particle size polydispersity from 1.1 to 4.0. This invention also relates to a method for producing said dry powder compositions and a system for vaccination of poultry by inhalation.

Abstract: The invention relates to a recombinant Mononegavirales virus (MV) vector comprising a foreign gene that is flanked by non-coding regions of a MV virus gene.

Abstract: The present invention discloses the method of making and using a novel, non-infective, paramyxovirus vaccine. Paramyxovirus structural proteins within a virus-like particle (VLP) comprise one example of such a vaccine. It is observed that the presence of matrix protein, alone, is sufficient and necessary to provide an effective VLP release. Co-expression of four paramyxovirus structural proteins, however, result in the release of non-infective VLPs with densities and efficiencies of release similar to that of infective particles. Representative diseases wherein a VLP vaccine might be useful include, but are not limited to, Newcastle disease, measles, respiratory syncytial virus infection, and parainfluenza 3 virus infection.

Abstract: The present invention features immunogenic compositions comprising codon modified genes that encode viral proteins and/or glycoproteins or fragments. The immunogenic compositions of the invention are useful in various methods of treatment, such as preventing or treating viral infection. Also provided in the present invention are kits and instructions for use.

Abstract: The present invention discloses and claims chimeric virus like particles (VLPs) that express and/or contains Newcastle disease matrix protein. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising chimeric VLPs of the inventions. The invention also includes methods of making and administrating chimeric VLPs to vertebrates, including methods of inducing immunity to infections.

Abstract: The present invention provides a novel use of coccidian, specifically relates to the use of coccidian as a vaccine live vector. The present invention further provides a live vaccine with coccidian as a vector, which is transgenic coccidian capable of expressing exogenous protein or stably transfected coccidian that contain expression vector and can express exogenous coccidian. The present coccidian vector live vaccine can induce organisms to simultaneously generate protective humoral and cellular immune responses (including the mucosal immune response), as well as generate memory responses, which can be readily carried out and has stable effect and high biological safety without generating immune tolerance.

Abstract: A CpG DNA adjuvant in avian vaccines is disclosed, which includes an immunostimulatory oligodeoxynucleotide (ODN) having a sequence of SEQ ID NO: 2. The CpG DNA adjuvant in avian vaccines is advantageous to carry out large-scale production, specifically enhance avian innate and adaptive immune responses, and the CpG DNA adjuvant is hardly to be digested by DNase due to its particular structures.

Abstract: The invention relates to new vaccine compositions for vaccinating birds.

Abstract: A purpose of the present invention is to provide a vaccine for in ovo inoculation effective for prevention of any fowl viral diseases. A fowl vaccine for in ovo inoculation with high efficacy in view of safety as well wherein, by holding such live viruses on a virus-adsorbing agent through adsorption that have been difficult for practical usage as a vaccine for in ovo inoculation, viral growth in embryonated chicken eggs after in ovo inoculation is retarded to thereby reduce pathogenicity of the viruses to embryo to avoid reduction in hatching rate and to alleviate severity in clinical symptoms after hatching. A virus-adsorbing agent to be used in the vaccine includes an aluminum compound such as aluminum hydroxide gel, potassium alum and the like.

Abstract: This invention relates to genetically engineered Newcastle disease viruses and viral vectors which express heterologous genes or mutated Newcastle disease viral genes or a combination of viral genes derived from different strains of Newcastle disease virus. The invention relates to the construction and use of recombinant negative strand NDV viral RNA templates which may be used with viral RNA-directed RNA polymerase to express heterologous gene products in appropriate host cells and/or to rescue the heterologous gene in virus particles. In a specific embodiment of the invention, the heterologous gene product is a peptide or protein derived from the genome of a human immunodeficiency virus. The RNA templates of the present invention may be prepared by transcription of appropriate DNA sequences using any DNA-directed RNA polymerase such as bacteriophage T7, T3, SP6 polymerase, or eukaryotic polymerase I.

Abstract: The present invention discloses methods for inducing regression of a tumor in a subject by administering a pharmaceutical composition comprising a lentogenic strain of Newcastle disease virus (NDV). A preferred viral strain of NDV for inducing regression of a tumor in a subject is a clonal strain of NDV, the NDV HUJ. The methods of the present invention are particularly useful for inducing regression of tumors in patients unresponsive to conventional anti-cancer therapies.

Abstract: The present invention relates to poultry vaccines for prevention of Newcastle disease.